Epicardial standalone left atrial appendage clipping for prevention of ischemic stroke in patients with atrial fibrillation contraindicated for oral anticaogulation.
hemorrhagic complication
ischemic stroke prevention
left atrial appendage occlusion
oral anticoagulation therapy
totally thoracoscopic surgery
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
14
01
2020
revised:
26
05
2020
accepted:
28
05
2020
pubmed:
5
6
2020
medline:
29
7
2021
entrez:
5
6
2020
Statut:
ppublish
Résumé
The most appropriate treatment for stroke prevention in standalone atrial fibrillation patients with a high CHADS2VASC score contraindicated for oral anticoagulation (OAC) or novel OAC (NOAC) still needs to be defined. Percutaneous left atrial appendage (LAA) closure devices are available, but because of their endocardial positioning need a period of antiplatelet therapy (APT). This study aimed to evaluate the safety and efficacy of epicardial left atrial appendage clipping in patients contraindicated for (N)OAC and APT. We describe a standalone totally thoracoscopic LAA clipping of forty-five consecutive patients with nonvalvular atrial fibrillation (NVAF; 32 males; age, 73.1 ± 7.4 years; CHADVASC, 6.5 ± 1.1; HAS-BLED 4.9 ± 0.9) with absolute contraindications to (N)OAC. The patients were selected by a multidisciplinary Heart Team. Sixty percent had a previous ischemic stroke and 51% a history of the hemorrhagic event and 22% both. All patients were implanted with an LAA epicardial clip, guided by preoperative computed tomography and intraoperative transesophageal echocardiography. The mean procedural duration was 52.3 ± 12.6 minutes with postprocedural extubation interval of 22.8 ± 14.6 minutes. No procedure-related complications occurred. Intraprocedural transesophageal echocardiography (TEE) showed complete LAA occlusion in all patients. At a mean follow-up of 16.4 ± 9.1 months (range, 2-34), with all patients off (N)OAC or APT, no ischemic stroke or hemorrhagic complications occurred. computed tomography or TEE at follow-up demonstrated a correct LAA occlusion in all with mean stumps of 3.3 ± 2.8 mm. Thoracoscopic epicardial closure of the LAA with the AtriClip PRO2 device is a potentially safe and efficient treatment for stroke prevention in patients with NVAF contraindicated for anticoagulant therapy or APT.
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2187-2191Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016(37):2893-2962.
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation. 2014;130:e199-e267.
Huisman MV, Rothman KJ, Paquette M, et al. The changing landscape for stroke prevention in AF: findings from the GLORIA-AF Registry Phase 2. J Am Coll Cardiol. 2017;69:777-785.
Southworth M, Reichman M, Unger E. Dabigatran and postmarketing reports of bleeding. New Engl J Med. 2013;368:1272-1274.
Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin-The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol. 2014;63:2141-2147.
Goodman SG, Wojdyla DM, Piccini JP, et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol. 2014;63:891-900.
Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955-962.
Murthy SB, Gupta A, Merkler AE, et al. Restarting anticoagulant therapy after intracranial hemorrhage-a systematic review and meta-analysis. Stroke. 2017;48:1594-1600.
Blackshear J, Odell J. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61(2):755-759.
Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374(9689):534-542.
Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL Trial. J Am Coll Cardiol. 2014;64:1-12.
Lee RJ, Vassallo P, Kruse J, et al. A randomized, prospective pilot comparison of 3 atrial appendage elimination techniques: Internal ligation, stapled excision, and surgical excision. J Thorac Cardiovasc Surg. 2016 Oct;152(4):1075-1080.
Healey JS, Crystal E, Lamy A, et al. Left Atrial Appendage Oclusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J. 2005;150:288-293.
Kanderian A, Gillinov A, Pettersson G, Blackstone E, Klein A. Success of surgical left atrial appendage closure-assessment by transesophageal echocardiography. J Am Coll Cardiol. 2008;52(11):924-929.
Geuzebroek G, Bentala M, Molhoek S, Kelder J, Schaap J, Van Putte B. Totally thoracoscopic left atrial maze: standardized, effective and safe. Interact Cardiovasc Thorac Surg. 2016;22:259-264.
Ailawadi G, Gerdisch MW, Harvey RL, et al. Exclusion of left atrial appendage with a novel device: early results of multicenter trial. J Thorac Cardiovasc Surg. 2011;142(5):1002-1009.
Caliskan E, Sahin A, Yilmaz M, et al. Epicardial left atrial appendage AtriClip occlusion reduces the incidence of stroke in patients with atrial fibrillation undergoing cardiac surgery. Europace. 2018;20:e105-e114.
Jones W, Williams L, Meschina J. Validating the Questionnaire for Veriyfying stroke free status (QSVS by neurological history and examination. Stroke. 2001;32:2232-2236.
Starck CT, Steffel J, Emmert MY, et al. Epicardial left atrial appendage clip occlusion also provides the electrical isolation of the leftatrial appendage. Interact Cardiovasc Thorac Surg. 2012;15:416-418.
Vos LM, Kotecha D, Geuzebroek G, et al. Totally thoracoscopic ablation for atrial fibrillation. A systematic safety analysis. Europace. 2018;20(11):1790-1797.
Ohtsuka T, Ninomiya M, Nonaka T, Hisagi M, Ota T, Mizutani T. Thoracoscopic stand-alone left atrial appendectomy for thromboembolism prevention in nonvalvular atrial fibrillation. J Am Coll Cardiol. 2013;62(2):103-107.
Wehbe MS, Doll N, Merk Dr. Fatal complication associated with surgical left atrial appendage exclusion. J Thorac Cardiovasc Surg. 2018;156:e207-e208.